Special Issue "mTOR Pathway in Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 October 2017) | Viewed by 53166
Interests: mTOR; protein translation; hypoxia; Tuberous Sclerosis Complex; autophagy; cancer; signalling; protein kinases; angiogenesis; mitochondrial biogenesis
Special Issues, Collections and Topics in MDPI journals
Mechanistic target of rapamycin (mTOR) is often referred to as a master regulator of cell growth control and is aberrantly activated in many cancers. As well as enhancing tumour growth and proliferative rate, mTOR is also involved in metabolic transformation, neovascularisation and metastasis. Regulation of tumour growth by mTOR involves protein translation, hypoxia signalling, autophagy and synthetic anabolic pathways in the pentose phosphate pathway that builds tumour mass while maintaining energy and nutrient homeostasis. mTOR is also a critical driver of epithelial–mesenchymal transition, necessary for cancer cell differentiation status, cancer stem-cells, drug resistance, motility and metastasis. Our knowledge of mTOR signalling has been markedly accelerated by research on rare genetic disorders where patients are predisposed to tumours. Given the plethora of activities that mTOR is involved in, it is not surprising that mTOR is upregulated during cancer progression. mTOR activation often correlates with metastasis, poor patient survival and resistance to anticancer agents such as chemotherapy. Consequently, the mTOR signalling pathway has received a lot of clinical interest. The use of rapalogues and ATP-competitive inhibitors of mTOR have shown clinical promise for the treatment of a range of cancers. In summary, this Special Issue will review the complexity of mTOR signalling, its involvement in cancer progression, how mTOR inhibitors have made a clinical impact and future research directions.
Dr. Andrew Tee
Dr. James Murray
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.